Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.
Regardless of the quality of the raw materials used in bioproduction processes, variability is a very common threat that can be addressed, says Thermo Fisher executive.
The summer months are traditionally slow on movements across the industry, but July saw a number of manufacturing partnership deals take place as companies look ahead to product commercialization.
The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.
Thermo Fisher invests into bioproduction capabilities as ‘single use continues to reshape the face of the industry,’ says single-use technology executive.
Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.
